Abstracts tagged "prescribing trends and rheumatoid arthritis (RA)"

Abstract Number: 2348 • 2018 ACR/ARHP Annual Meeting
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Maria A. Lopez-Olivo¹, Jude K. A. des Bordes¹, Gregory Pratt² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of…
Abstract Number: 922 • 2017 ACR/ARHP Annual Meeting
Biologic DMARD Prescribing Patterns in Elderly Patients with Rheumatoid Arthritis
Britney Jones¹, Imran Hassan², Walter P. Maksymowych³ and Elaine Yacyshyn⁴, ¹University of Alberta, Edmonton, AB, Canada, ²EPICORE Centre, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Rheumatoid arthritis is a chronic inflammatory process involving progressive destruction of joints. Currently, 30% of rheumatoid arthritis (RA) patients are over the age of…
Abstract Number: 2106 • 2015 ACR/ARHP Annual Meeting
Intensification to Triple Therapy Non-Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States from 2009 to 2014
Jeffrey A. Sparks¹, Alexis A. Krumme², Olga S. Matlin³, Gregory Brill², William H. Shrank³, Niteesh K. Choudhry² and Daniel H. Solomon^2,4, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³CVS Caremark, Woonsocket, RI, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Several trials suggest that triple therapy with non-biologic disease-modifying antirheumatic drugs (ttDMARD) has similar efficacy compared to biologic DMARDs (bDMARD) for patients with RA.…
Abstract Number: 1982 • 2013 ACR/ARHP Annual Meeting
Development and Validation Of Medication Assessment Tools Specific For Rheumatoid Arthritis
Louise Grech^1,2, Bernard Coleiro^1,3, Anthony Serracino Inglott¹, Lilian M. Azzopardi¹, Victor Ferrito¹ and Andrew A. Borg^3,4, ¹Pharmacy, University of Malta, Msida, Malta, ²Clinical Pharmacy, Mater Dei Hospital, Msida, Malta, ³Medicine, Mater Dei Hospital, Msida, Malta, ⁴Medicine, University of Malta, Msida, Malta
Background/Purpose: Medication assessment tools can be defined as evidence-based instruments intended for the evaluation of prescribing trends and monitoring of adherence to established guidelines. Medication…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].